Press Release

Printer Friendly VersionView printer-friendly version << Back

Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference

NEWARK, Calif., March 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview on Wednesday, March 21 at the 28th Annual Oppenheimer Healthcare Conference. The conference will be held at The Westin New York Grand Central hotel in New York, NY.

The Protagonist Therapeutics presentation is scheduled for 3:20 pm Eastern Time.

A live audio webcast of the presentation may be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at A replay of the presentation will be available for 30 days following the presentation.

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. Two of its clinical stage product candidates, PTG-100 and PTG-200, are oral targeted therapy drugs being developed for inflammatory bowel diseases (IBD). The alpha-4-beta-7 integrin antagonist peptide PTG-100 is currently in a Phase 2b clinical trial for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist peptide PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers to support further development in Crohn's disease.  Both alpha-4-beta-7 integrin and IL-12/23 pathway blockade are approaches that have been validated through FDA-approved injectable antibody drugs. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200.  Protagonist has also applied its versatile platform outside of the GI disease areas and is developing an injectable hepcidin mimetic, PTG-300, for the treatment of anemia related to rare blood diseases with an initial focus on beta-thalassemia. PTG-300 recently completed a Phase 1 clinical trial which established pharmacodynamic-based clinical proof-of-concept in normal healthy volunteers. The U.S. Food and Drug Administration has granted Orphan Drug Designation to PTG-300 for beta-thalassemia.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit



Cision View original content with multimedia:

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Mobile: +1 415-690-0210, email: OR For Investors: The Trout Group, Marcy Nanus, 646-378-2927,